JHL Biotech’s Clinical Trial Application Accepted by China for Bevacizumab Biosimilar to Treat Colorectal, Lung, and Ovarian Cancers

JHL Logo High Resolution (PRNewsFoto/JHL Biotech, Inc.)HSINCHU, Taiwan and WUHAN, China, April 16, 2018 /PRNewswire/ -- JHL Biotech announced today that the China Food and Drug Administration (CFDA) has accepted for review JHL's Clinical Trial Application for a proposed bevacizumab biosimilar, JHL1149, to treat cancer. JHL1149 is a...


Leave a comment

Your email address will not be published.


*